Back To Search Results

Gastric Polyp

Editor: Roopma Wadhwa Updated: 7/10/2023 2:35:37 PM


Gastric polyps are distinct intraluminal projections of mucosal or submucosal tissue. These lesions represent proliferative growth that can contain the potential for malignant transformation. Gastric polyps have many subsets, the most commonly seen and described are the triad of gastric hyperplastic polyps (GHP) characterized by pronounced foveolar hyperplasia, fundic gland polyps (FGP) characterized by dilated and irregularly budded fundic glands predominantly lined by parietal cells with smaller proportion of chief cells, and adenomatous polyps characterized by low-grade glandular dysplasia.

However, within the umbrella of gastric polyps also falls a much broader differential for the lesion including carcinoids (grouping of endocrine cells resulting in projecting lesion), infiltrative lesions (xanthomas, lymphoid proliferations), mesenchymal proliferations (gastrointestinal stromal tumors, leiomyoma, fibroid polyps), and hamartomatous lesions (Peutz-Jegher, Cowden, juvenile) all of which may produce a mucosal/submucosal protrusion appearing as a gastric polyp. It is difficult to discern the likely histopathology of a polyp from simple inspection via endoscopy, in most instances, biopsy and histopathologic evaluation are necessary to guide management.[1][2][3][4][5]


Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care


The vast majority of gastric polyps are found incidentally on endoscopic investigation or autopsy, and as such, the cause of their formation is poorly understood. The development of GHPs is thought to be related to chronic inflammation commonly associated with H. pylori infection and atrophic gastritis. The association with H. Pylori stems from the finding that in many cases (70%), GHPs will regress within a year after eradication of H. Pylori infection, assuming no reinfection occurs. Less is known about the cause of FGPs. However, several studies have indicated an association with chronic PPI usage, which suggests that a mechanism involving gastric acid suppression may lie in the background of their development.

The most commonly associated risks for the development of adenoma include age and chronic inflammation/irritation of the tissue involved, which results in intestinal metaplasia and subsequent risk for malignant transformation typically attributed to acquired mutations involving the expression of p53 and Ki-67 genes. It is worth mentioning here that the finding of gastric adenoma in a young patient can be indicative of the presence of a more concerning underlying genetic condition, familial adenomatous polyposis (FAP), which merits further investigation.[2][6][7]


The prevalence and distribution of gastric polyps vary widely between sources, but from the review of several high-powered studies, the prevalence of gastric polyps in patients undergoing endoscopy was between 2% to 6%. Of those, GHPs represent 17% to 42%, FGPs represent 37% to 77%, adenomas represent 0.5% to1%, and malignant neoplasm represented approximately 1% to 2%. Gastric polyps are most likely to be found in the fundus and have an increasing prevalence associated with increased age. Distribution amongst the sexes varies widely in the literature. However, females are more likely to have FGPs, and males are more likely to have adenoma. Variation in diet and lifestyle across different populations contributes to the wide variations reported between studies.[8][9][10]

History and Physical

The vast majority of gastric polyps are asymptomatic, with over 90% being found incidentally on endoscopy. The most common complaints associated with the finding of gastric polyps are dyspepsia, acid reflux, heartburn, abdominal pain, early satiety, gastric outlet obstruction, gastrointestinal bleed, anemia, fatigue, and iron deficiency. Only in rare circumstances would a physical exam be helpful in the finding of gastric polyps as most are less than 2cm in size.[11][12]


As the majority of gastric polyps are asymptomatic or found incidentally, evaluation most commonly begins with some complaint of dyspepsia or the finding of anemia on routine CBC. It is possible to see gastric polyps on noninvasive imaging, e.g., computed tomography (CT) scan or magnetic resonance imaging (MRI), but only in the rare case of a very large polyp. The gold standard for evaluation for gastric polyps consists of esophagogastroduodenoscopy (EGD) performed by an experienced practitioner.[13]

Treatment / Management

As it is difficult to discern the underlying histopathology of a gastric polyp from visualization under endoscopy alone, biopsy and en-bloc resection are required to guide management. It is well known that malignant potential increases with an increased size of the lesion, and as such, it is advised that all lesions greater than 10 mm be removed by endoscopic mucosal resection (EMR). A more conservative approach taken by some practitioners suggests the removal of all polyps greater than 5 mm. Prior to any manipulation of the mucosa, a dose of intravenous proton pump inhibitor is administered to reduce the acidity of the environment and improve hemostasis. In many cases following endoscopy with biopsy, a PPI is continued for 4 to 8 weeks to improve healing at the biopsy/resection sites. If pathology reveals H. Pylori infection, antibiotic therapy is initiated. When polyps are removed or biopsied, or there is a finding of gastritis, it is common for the endoscopist to perform concurrent gastric mapping to determine the etiology of gastritis involving mucosal biopsy via cold forceps at multiple locations within the stomach.

Management and follow-up after biopsy is guided by the histopathologic findings of the polyps removed during esophagogastroduodenoscopy (EGD). For GHPs removed by EGD without finding dysplasia, a single repeat EGD is recommended at one year of follow-up. If H. Pylori is found in biopsies associated with GHP, then a repeat EGD is often performed in 3-6 months for repeat biopsy to confirm eradication of infection and to track the regression of gastric polyps. For FGP, if there is a history of chronic PPI use, then discontinuation when possible is recommended, and 1-year follow-up EGD is performed when lesions greater than 5 to 10 mm were found on initial EGD and to track response to therapy. The finding of adenoma on microscopic evaluation of gastric polyp indicates the need for 1-year follow-up EGD. In a patient less than 40 years old where multiple adenomas are seen on EGD, extensive family history taking and colonoscopy is recommended to rule out FAP. If dysplasia or early adenocarcinoma is detected on microscopic evaluation of a gastric polyp, repeat EGD is performed at 1 year and again at 3 years from initial endoscopy.[3][6][11][13][14](A1)

Differential Diagnosis

Following are some important differentials that should be considered while making the diagnosis of gastric polyps:

  • Gastric hyperplastic polyp
  • Fundic gland polyp
  • Adenoma
  • Familial adenomatous polyposis
  • Carcinoma
  • Carcinoid
  • Xanthoma
  • Gastrointestinal stromal tumors
  • Leiomyoma
  • Fibroid polyps
  • Peutz-Jegher syndrome
  • Cowden syndrome
  • Juvenile polyps
  • Hemangioma
  • Lymphangioma
  • Lymphoma
  • Neuroma


Overall the finding of gastric polyps carries with it a good prognosis with some studies indicating a finding of malignancy in less than 2% of polyps investigated. Characteristics of polyps that indicate a poorer prognosis include large size, the advanced age of the patient, and the finding of multiple adenomas. It is known that the risk of finding dysplasia or malignancy increases greatly in lesions larger than 20 mm, in older patients, and that the finding of multiple adenomas may indicate the presence of FAP which has a high risk for the development of adenocarcinoma.[3]


Gastric polyps can complicate and have the following consequences:

  • Bleeding
  • Perforation
  • Infection
  • Cancer
  • Ileus
  • Obstruction

Deterrence and Patient Education

Gastric cancer is the third most common cause of death related to cancer worldwide. As gastric polyps can represent precancerous lesions, it is possible that with proper management of gastric polyps, this number may be reduced. Recommendations that may decrease a patient’s risk for developing gastric polyps include dietary and lifestyle changes including but not limited to decreasing alcohol intake, cessation of smoking, decreasing dietary fat, and increasing fiber intake.[3]

Enhancing Healthcare Team Outcomes

Gastric polyps may be found during investigation and workup of patients’ complaints of weakness, fatigue, and dyspepsia and while they can contribute to these symptoms, they are nearly always incidental findings during endoscopic evaluation performed to rule out other gastric pathologies such as peptic ulcer disease, Barrett esophagus, delayed gastric emptying, etc. As such, the decision and responsibility of properly managing gastric polyps rest with the specialist. Guidelines such as those laid out by the American Society of Gastrointestinal Endoscopy (ASGE) are in place for this reason and can be applied to direct specialists when they encounter pathologies such as GHP, FGP, and adenomatous polyps.

Since the management of gastric polyps is directed by a specialty service, interprofessional communication between the gastroenterologist and the primary care clinician is essential to ensuring the appropriate information is conveyed to patients and that they receive the necessary follow-up dependent on their specific pathology found during the endoscopic evaluation.[3] [Level 1] Pathologists, anesthetists, nurses, and surgical technicians are involved in the diagnosis, treatment, and care of patients with gastric polyps. Thus, interprofessional collaboration is important in achieving optimal patient outcomes.



Park DY, Lauwers GY. Gastric polyps: classification and management. Archives of pathology & laboratory medicine. 2008 Apr:132(4):633-40     [PubMed PMID: 18384215]


Markowski AR, Markowska A, Guzinska-Ustymowicz K. Pathophysiological and clinical aspects of gastric hyperplastic polyps. World journal of gastroenterology. 2016 Oct 28:22(40):8883-8891     [PubMed PMID: 27833379]


Carmack SW, Genta RM, Graham DY, Lauwers GY. Management of gastric polyps: a pathology-based guide for gastroenterologists. Nature reviews. Gastroenterology & hepatology. 2009 Jun:6(6):331-41. doi: 10.1038/nrgastro.2009.70. Epub     [PubMed PMID: 19421245]


Burt RW. Gastric fundic gland polyps. Gastroenterology. 2003 Nov:125(5):1462-9     [PubMed PMID: 14598262]

Level 3 (low-level) evidence


Islam RS, Patel NC, Lam-Himlin D, Nguyen CC. Gastric polyps: a review of clinical, endoscopic, and histopathologic features and management decisions. Gastroenterology & hepatology. 2013 Oct:9(10):640-51     [PubMed PMID: 24764778]


Markowski AR, Guzinska-Ustymowicz K. Gastric hyperplastic polyp with focal cancer. Gastroenterology report. 2016 May:4(2):158-61. doi: 10.1093/gastro/gou077. Epub 2014 Oct 31     [PubMed PMID: 25361760]

Level 3 (low-level) evidence


Abraham SC, Singh VK, Yardley JH, Wu TT. Hyperplastic polyps of the stomach: associations with histologic patterns of gastritis and gastric atrophy. The American journal of surgical pathology. 2001 Apr:25(4):500-7     [PubMed PMID: 11257625]


Cao H, Wang B, Zhang Z, Zhang H, Qu R. Distribution trends of gastric polyps: an endoscopy database analysis of 24 121 northern Chinese patients. Journal of gastroenterology and hepatology. 2012 Jul:27(7):1175-80. doi: 10.1111/j.1440-1746.2012.07116.x. Epub     [PubMed PMID: 22414211]

Level 2 (mid-level) evidence


Carmack SW, Genta RM, Schuler CM, Saboorian MH. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. The American journal of gastroenterology. 2009 Jun:104(6):1524-32. doi: 10.1038/ajg.2009.139. Epub 2009 Apr 28     [PubMed PMID: 19491866]

Level 2 (mid-level) evidence


Argüello Viúdez L, Córdova H, Uchima H, Sánchez-Montes C, Ginès À, Araujo I, González-Suárez B, Sendino O, Llach J, Fernández-Esparrach G. Gastric polyps: Retrospective analysis of 41,253 upper endoscopies. Gastroenterologia y hepatologia. 2017 Oct:40(8):507-514. doi: 10.1016/j.gastrohep.2017.01.003. Epub 2017 Feb 20     [PubMed PMID: 28222897]

Level 2 (mid-level) evidence


Goddard AF, Badreldin R, Pritchard DM, Walker MM, Warren B, British Society of Gastroenterology. The management of gastric polyps. Gut. 2010 Sep:59(9):1270-6. doi: 10.1136/gut.2009.182089. Epub 2010 Jul 30     [PubMed PMID: 20675692]


Sonnenberg A, Genta RM. Prevalence of benign gastric polyps in a large pathology database. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2015 Feb:47(2):164-9. doi: 10.1016/j.dld.2014.10.004. Epub 2014 Nov 8     [PubMed PMID: 25458775]

Level 2 (mid-level) evidence


ASGE Standards of Practice Committee, Evans JA, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Fisher DA, Foley K, Hwang JH, Jue TL, Lightdale JR, Pasha SF, Sharaf R, Shergill AK, Cash BD, DeWitt JM. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointestinal endoscopy. 2015 Jul:82(1):1-8. doi: 10.1016/j.gie.2015.03.1967. Epub 2015 Apr 29     [PubMed PMID: 25935705]


Ji F, Wang ZW, Ning JW, Wang QY, Chen JY, Li YM. Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. World journal of gastroenterology. 2006 Mar 21:12(11):1770-3     [PubMed PMID: 16586550]

Level 1 (high-level) evidence